证券之星消息，截至2025年12月3日收盘，尚荣医疗(002551)报收于3.94元，下跌0.25%，换手率 1.84%，成交量11.25万手，成交额4439.66万元。 12月3日的资金流向数据方面，主力资金净流入340.88万元，占总成交额7.68%，游资资金净流出12.3万 元，占总成交额0.28%，散户资金净流出328.58万元，占总成交额7.4%。 近5日资金流向一览见下表： 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-03 | 3.94 -0.25% | 340.88万 | 7.68% | -12.30万 | -0.28% | -328.58万 | -7.40% | | 2025-12-02 | 3.95 0.00% | 66.49万 | 1.59% | -79.83万 | -1.90% | 13.33万 | 0.32% | | 2025-12-0 ...

Core Insights - The stock of Shangrong Medical (002551) closed at 3.95 yuan on December 1, 2025, with an increase of 0.77% and a trading volume of 120,900 hands, resulting in a transaction amount of 47.78 million yuan [1][2]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85% [3]. - The net profit attributable to shareholders was -35.13 million yuan, a decline of 338.5% year-on-year [3]. - The third quarter alone saw a main revenue of 225 million yuan, down 39.25% year-on-year, and a net profit of -27.37 million yuan, a drop of 4004.28% year-on-year [3]. Market Position - Shangrong Medical's total market capitalization is 3.34 billion yuan, significantly lower than the industry average of 11.16 billion yuan, ranking 98 out of 124 in the medical device industry [3]. - The company has a negative price-to-earnings ratio of -71.31, compared to the industry average of 59.83, indicating poor profitability [3]. - The gross margin stands at 14.35%, which is substantially below the industry average of 51.22%, ranking 119 out of 124 [3]. Capital Flow Analysis - On December 1, 2025, the net inflow of main funds was 1.38 million yuan, accounting for 2.89% of the total transaction amount, while retail investors saw a net inflow of 1.11 million yuan, making up 2.32% [1][2]. - Over the past five days, the main funds have fluctuated, with notable net inflows and outflows, indicating varying investor sentiment [2].

Group 1: BYD Performance - BYD announced a production of 474,200 new energy vehicles (NEVs) and sales of 480,200 NEVs in November 2025 [1] - Cumulative production for the year reached 4,117,600 units, representing a year-on-year increase of 7.29% [1] - Cumulative sales for the year totaled 4,182,000 units, with a year-on-year growth of 11.30% [1] - In November, BYD exported 131,900 NEVs and installed approximately 27.669 GWh of power batteries and energy storage batteries [1] Group 2: Investment Initiatives - Lushin Venture Capital plans to establish a 400 million yuan investment fund focusing on life sciences, advanced manufacturing, and AI [2] - Chint Electric's wholly-owned subsidiary intends to invest up to 201 million yuan in a green private equity investment fund with a total scale of 700 million yuan [8] Group 3: Corporate Actions - Qianwei Central Kitchen will conduct a shareholder reward activity, offering a product package worth 200 yuan to individual shareholders holding 100 shares or more [3] - Huaxia Happiness plans to use trust beneficiary rights to offset financial debts totaling up to 24 billion yuan as part of its debt restructuring plan [4] - Tailong Pharmaceutical's controlling shareholder is planning a share transfer, leading to a temporary suspension of the company's stock [5] - ST Xianhe has applied to revoke other risk warnings, pending approval from the Shenzhen Stock Exchange [6] - *ST Yuancheng's stock will be delisted due to a market value below 500 million yuan for 20 consecutive trading days [7] Group 4: Sales and Contracts - SAIC Group reported sales of 4,108,000 vehicles from January to November 2025, a year-on-year increase of 16.4% [10] - Geely Automobile's total sales in November reached 310,428 units, marking a 24% increase year-on-year [11] - Far East Holdings' subsidiaries secured contracts worth 2.383 billion yuan in November, positively impacting future earnings [18] - Samsung Medical's subsidiary signed a contract for an annual bidding project in Indonesia worth approximately 160 million yuan [19] - Zhongchao Holdings' subsidiaries recently won contracts totaling 1.318 billion yuan [20] - Changhua Group received a project development notice from a domestic automaker, with an expected total sales amount of approximately 732 million yuan [21]

Fundraising Overview - The company has been approved to publicly issue convertible bonds with a total face value of RMB 750 million, with a term of 6 years [2] - The actual net amount raised after deducting underwriting fees and other expenses is RMB 733.35 million [2][3] Fund Management - The company has established a special account for the management and use of the raised funds, in compliance with relevant regulations [4] - A tripartite supervision agreement has been signed with multiple banks and the sponsor to ensure the funds are used solely for the "high-end medical consumables industrialization project" [4] Fund Usage and Termination - As of the announcement date, all funds from the special accounts have been fully utilized, and the accounts are no longer in use [7] - The company has decided to terminate the "high-end medical consumables industrialization project" and will use the remaining funds of approximately RMB 358.70 million to permanently supplement working capital [6][7]

Group 1 - The stock of Shangrong Medical (002551) closed at 3.86 yuan on November 27, 2025, with a market capitalization of 3.264 billion yuan, reflecting a 0.26% increase from the previous trading day [1] - The company announced the completion of the public issuance of convertible bonds on February 20, 2019, raising a total of 750 million yuan, with a net amount of 733 million yuan allocated for a "high-end medical consumables industrialization project" [1] - The board and shareholders approved the termination of the project on August 23 and September 12, 2025, with approximately 359 million yuan of the remaining funds being permanently allocated to supplement working capital [1] Group 2 - All funds from the five special accounts for the raised capital have been fully utilized, and the related accounts have been closed, with the tripartite supervision agreement also terminated [1]

证券之星消息，截至2025年11月27日收盘，尚荣医疗(002551)报收于3.86元，上涨0.26%，换手率 1.63%，成交量9.96万手，成交额3839.69万元。 11月27日的资金流向数据方面，主力资金净流出71.29万元，占总成交额1.86%，游资资金净流出183.02 万元，占总成交额4.77%，散户资金净流入254.31万元，占总成交额6.62%。 近5日资金流向一览见下表： | 指标 | 尚荣医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 32.64亿元 | 110.26亿元 | 99 124 | | 净资产 | 27.3亿元 | 38.93亿元 | 57 124 | | 净利润 | -3512.53万元 | 2.12亿元 | 111 124 | | 市盈率(动) | -69.69 | 56.75 | - 124 | | 市净率 | 1.26 | 3.87 | 15 124 | | 毛利率 | 14.35% | 51.22% | 119 124 | | 净利率 | -4.6% | 9.57% | 103 124 | | ROE ...

证券代码：002551 证券简称：尚荣医疗 公告编号：2025-052 关于公开发行可转换公司债券募集资金专户销户完成的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 根据中国证券监督管理委员会于 2018 年 12 月 5 日签发的证监许可 [2018]1843 号文《关于核准深圳市尚荣医疗股份有限公司公开发行可转换公司债 券的批复》深圳市尚荣医疗股份有限公司（以下简称"公司"或"尚荣医疗"） 获准社会公开发行面值总额 75,000 万元的可转换公司债券，期限 6 年。公开发 行可转换公司债券应募集资金人民币 750,000,000.00 元，发行价格为每张人民币 100.00 元，募集资金总额为人民币 750,000,000.00 元。本次发行可转换公司债券 募集资金总额扣除保荐承销费用不含税金额 14,150,943.40 元，其他发行费用不 含税金额 2,502,830.20 元，实际募集资金净额为人民币 733,346,226.40 元，上述 资金于 2019 年 2 月 20 日到位，业经大华会计师事务所（特殊普通合伙 ...

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a slight increase of 2.7% on November 24, 2025, closing at 3.81 yuan, despite facing significant net outflows from major and retail investors in recent days [1][2]. Financial Performance - Shangrong Medical reported a total revenue of 754 million yuan for the first three quarters of 2025, representing a year-on-year decline of 24.85% [3]. - The company recorded a net profit attributable to shareholders of -35.13 million yuan, a significant drop of 338.5% year-on-year [3]. - The third quarter of 2025 saw a single-quarter revenue of 225 million yuan, down 39.25% year-on-year, with a net profit of -27.37 million yuan, reflecting a staggering decline of 4004.28% [3]. Market Position - As of November 24, 2025, Shangrong Medical's total market capitalization stands at 3.22 billion yuan, which is significantly lower than the industry average of 10.98 billion yuan [3]. - The company's net asset value is 2.73 billion yuan, compared to the industry average of 3.89 billion yuan [3]. - Shangrong Medical's price-to-earnings ratio is -68.78, while the industry average is 55.96, indicating poor profitability [3]. Profitability Metrics - The gross margin for Shangrong Medical is 14.35%, which is substantially lower than the industry average of 51.22% [3]. - The net margin stands at -4.6%, compared to the industry average of 9.57% [3]. - Return on equity (ROE) is -1.34%, significantly below the industry average of 0.15% [3]. Recent Trading Activity - On November 24, 2025, the stock experienced a trading volume of 181,000 hands and a transaction value of 68.649 million yuan [1]. - The net outflow of major funds was 2.58 million yuan, accounting for 3.76% of the total transaction value, while retail investors saw a net inflow of 4.23 million yuan, representing 6.16% of the total [1][2].

编号：2025-003 投 资 者 关 系 活 动 类 别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 ■其他（2025 年度深圳辖区上市公司投资者网上集体接待日活动） 参 与 单 位 名 称 及 人 员姓名 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）参与"2025 年度深圳辖区上市公司投资者网上集体接待日活动"的投资者 时间 2025 年 11 月 20 日 14:30-17:00 地点 全景路演（https://ir.p5w.net） 上 市 公 司 接 待 人 员 姓名 董事长、总经理：梁桂秋 副总经理、董事会秘书：林立 财务总监：游泳 独立董事：曾江虹 投 资 者 关 系 活 动 主 要 内 容 介 绍 本次投资者网上集体接待日活动采用网络远程的方式举行，主要问答内 容如下： 1、请问海外业务的毛利为什么年年下滑？ 您好，感谢您对公司的关注！受进出口关税变动及运输成本增加所致。 谢谢！ 2、董事长好，我是公司小微股民，请问一下，公司的未来五年规划是怎 么安排的？另外，我国已经进入老年化社会，公司在设计，建设，配套医疗 ...

证券日报网讯尚荣医疗11月19日在互动平台回答投资者提问时表示，公司将在定期报告中披露对应期末 时点的股东数量等信息，请后续关注公司的定期报告。 （文章来源：证券日报） ...